Log in
Sign up free

Home
Sectors
Earnings
IPOs
Splits

Example searches

AAPL 10-K FY2019
Visa 10-Q
shopify
renewables AND wind 8-K 6-K NOT TAC
cryptocurrency OR "blockchain technology" OR bitcoin 2018-2021

ESPR Dashboard ESPR
Financials Financials
Data Charts Data
Insider Trades Insider
ESG ESG
All Filings Filings
8-K Filing 8-K

ESPR Esperion Therapeutics 8-K2021ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program

13 Jan 21

Files SEC

8-K Current report
99.1 ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program
Download Excel data file
View Excel data file

Content Analysis ?

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability

ESPR 8-K Filings

13 Jan 21 ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program
16 Dec 20 Other Events
15 Dec 20 ESPERION Appoints Sheldon Koenig as Chief Operating Officer
16 Nov 20 Entry into a Material Definitive Agreement

Filing View

Default size S M L
Default font Times Arial

Search this filing

All

Tables only

Footnotes only

Pre-defined:

Table of Contents

Get all this for free

Email alerts for new filings that match keywords or companies
Plot, compare & download financial data
10-K & 10-Q redlined comparisons
Advanced filing search & analysis
Sentiment analysis for financial filings
Favorites, search history, and more…

Sign up for free now More benefits

Top ESPR

Log in
Sign up
Benefits
Help
Contact
Terms
Privacy

© 2021 Eighty-Five Technologies Inc. Not affiliated with SEC EDGAR.